What Renerva does

Renerva, Inc. is a privately held medical device company founded in 2017 as a spin-off from the University of Pittsburgh Swanson School of Engineering and Cornell University, headquartered in Pittsburgh, Pennsylvania. The company is developing a portfolio of implantable peripheral nerve repair technologies built on a proprietary platform using decellularized porcine nerve tissue and its resulting extracellular matrix. Its lead product, the Renerva PNM-CAP™, is a bioabsorbable nerve capping device with an internal neuroinhibitory 3D matrix designed to prevent neuroma formation and chronic neuropathic pain following amputation; the device received FDA Investigational Device Exemption (IDE) approval in December 2025 and completed first-in-human implantation at The Ohio State University Wexner Medical Center in May 2026.

The underlying platform supports three additional pipeline products: PNM (an injectable Peripheral Nerve Matrix Hydrogel for nerve regeneration), PNM-G (a nerve conduit for bridging nerve gap injuries), and SND (a sutureless neurorrhaphy device for primary nerve repair). Preclinical evidence demonstrates up to 17-fold reduction in nerve growth and 3.5-fold reduction in evoked pain versus standard-of-care controls, and the device remodels into healthy host-derived tissue over time. The intended end users are orthopedic, plastic, neuro, and vascular surgeons performing amputations and nerve repairs at hospitals and surgical centers, addressing a U.S. population of more than two million amputees and approximately 500,000 new extremity amputations annually, of which up to 48% develop painful neuromas.

Renerva is pre-revenue: all products are investigational and not commercially available, and the company generates no product sales today. Its business model upon commercialization is expected to be direct sales of PNM-CAP™ and pipeline devices to hospitals and surgical centers via enterprise procurement channels, with a gtm focused on positioning PNM-CAP™ as the standard of care for neuroma prevention in amputations. The company has raised approximately $10 million cumulatively since 2017 from a mix of federal grants (NSF, NIH, MTEC, U.S. Department of Defense) and angel investors (Keiretsu Forum, Cowtown Angels, Rochester Angel Network, Chemical Angel Network), and operates with a lean 1–10 person team.

Name

Renerva

Legal name

Renerva, Inc.

Website

https://www.renerva.com/

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Renerva is a pre-revenue medical device company developing implantable peripheral nerve repair products based on decellularized porcine nerve tissue, led by the PNM-CAP™ nerve cap for neuroma prevention in amputees, targeting surgeons and hospitals.

Ownership category

akta.pro rank

Product category

Peripheral Nerve Repair Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Neural & Spinal Cord Regeneration (HLAAAGAI)

akta.pro secondary industries

Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK), Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation) (HLAHAEAB)

Keywords

• Peripheral nerve repair
• Nerve capping devices
• Neuroma prevention
• Decellularized nerve matrix
• Surgical nerve implants

Headquarters

HQ city

Pittsburgh

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales: Pre-revenue company developing implantable medical devices. Revenue will be generated through sales of PNM-CAP™ nerve cap devices and other pipeline products (PNM hydrogel, PNM-G graft, SND device) to hospitals and surgical centers upon FDA approval and commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Renerva develops and is advancing toward commercialization a portfolio of implantable peripheral nerve repair medical devices built on a proprietary decellularized porcine nerve extracellular matrix platform. Its lead product, the Renerva PNM-CAP™ nerve capping device, is a bioabsorbable implant designed to prevent neuroma formation and chronic neuropathic pain following amputation, with pipeline extensions in injectable nerve regeneration hydrogel, nerve gap conduits, and sutureless nerve repair devices. All products are investigational and not yet commercially available.

Product overview

Renerva is a medical device company developing a portfolio of implantable peripheral nerve repair technologies based on decellularized porcine nerve tissue. The core product is the Renerva PNM-CAP™ nerve capping device, which received FDA IDE approval and completed first-in-human implantation. The pipeline includes PNM (Peripheral Nerve Matrix Hydrogel) for injectable nerve regeneration, PNM-G (Peripheral Nerve Matrix Graft) as a nerve conduit for gap injuries, and SND (Sutureless Neurorrhaphy Device) for primary nerve repair. All products are investigational and not yet commercially available.

Differentiator

Problem solved

Functional benefit

Brands

• Renerva PNM-CAP™: A bioabsorbable nerve capping device made of porcine nerve extracellular matrix designed to prevent neuroma formation and chronic nerve pain. It features a neuro-inhibitory 3D matrix that prevents nerve growth and entanglement.
• PNM (Peripheral Nerve Matrix Hydrogel)
• PNM-G (Peripheral Nerve Matrix Graft)
• SND (Sutureless Neurorrhaphy Device)

Products and services

• Renerva PNM-CAP™ Nerve Cap Device A fully developed, packaged, and terminally sterilized bioabsorbable nerve capping device made of porcine nerve extracellular matrix, designed with a socket to entubulate the nerve end and a handling/anchoring tab for simple implantation. Features a proprietary internal neuroinhibitory 3D matrix that prevents nerve growth and entanglement for effective, long-term inhibition of neuroma and neuropathic pain. Available in multiple sizes for the prevention or treatment of neuroma in amputees. For use by orthopedic, plastic, neurosurgical, and vascular surgeons and their hospitals.
• PNM Peripheral Nerve Matrix Hydrogel Injectable gel derived from decellularized porcine nerve extracellular matrix designed to improve nerve growth and functional recovery following nerve injury by providing a neuroinductive interface between nerve and muscle. Pipeline product intended for surgeons treating peripheral nerve injuries.
• PNM-G Peripheral Nerve Matrix Graft Nerve conduit designed to bridge nerve gap injuries, using decellularized porcine nerve-derived hydrogel as a filler to improve electrophysiologic response and axon counts. Pipeline product for trauma and reconstructive surgeons treating peripheral nerve gap injuries.
• SND Sutureless Neurorrhaphy Device Device designed to obtain atraumatic primary nerve repair, enabling sutureless connection of severed nerve ends. Pipeline product for surgeons performing peripheral nerve repair procedures.

Quantifiable outcome

• Up to 17-fold reduction in nerve growth compared to standard of care controls
• +4 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core.

• University of PittsburghcoreStrategic or Co-development PartnerRenerva was founded out of the University of Pittsburgh Swanson School of Engineering in 2017. Key founders Bryan Brown and Lorenzo Soletti are researchers at Pitt. The company operates in partnership with Pitt's research ecosystem.
• Cornell UniversitycoreStrategic or Co-development PartnerRenerva was co-founded out of Cornell University in addition to University of Pittsburgh. The company has a satellite location in Ithaca, NY (Cornell's location) and maintains affiliation with Cornell's Life Science Ventures.
• The Ohio State University Wexner Medical CentercoreStrategic or Co-development PartnerClinical trial site for first-in-human implantation of Renerva PNM-CAP™ device. Dr. Amy M. Moore serves on Renerva's Medical and Scientific Advisory Board and is Interim Dean at Ohio State's College of Medicine.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Axogen: Leading pure-play peripheral nerve repair company (Avance nerve graft, AcroVal, Axoguard) selling directly to hand and microsurgeons. Most direct US peer to Renerva's nerve cap and graft platform.
• Polyganics: Netherlands-based developer of bioresorbable medical devices including Neurocap for neuroma prevention and nerve conduit/graft products — a close technological and indication overlap with Renerva's PNM-CAP.
• Checkpoint Surgical: US company developing nerve stimulation, identification, and repair tools for surgeons, including nerve protection and repair adjuncts. Comparable customer base of hand, plastic, and orthopedic surgeons.

Broad incumbents

• Integra LifeSciences: Large diversified MedTech with NeuraGen nerve guide and broader regenerative tissue portfolio. Competes in peripheral nerve repair and has the commercial scale Renerva lacks.
• Stryker: Global MedTech incumbent with orthopedic and surgical implant portfolios covering extremities and trauma. Represents a likely strategic acquirer in the peripheral nerve / regenerative medicine space.

Emerging players

• Alafair Biosciences: Emerging company developing hydrogel-based nerve and tendon protection devices (e.g., Nerve Tape) that compete at the soft-tissue nerve interface during surgical procedures.
• Acera Surgical: Emerging regenerative medicine company with proprietary electrospun matrices for soft tissue repair, an architectural and commercial analog in the regenerative implant space.
• Tulavi Therapeutics: Pre-commercial developer of autologous nerve tissue treatments targeting neuroma and phantom limb pain — same primary indication as Renerva's PNM-CAP.

Regional players

• Synapse Biomedical: Developer of neurostimulation devices (e.g., diaphragm pacing) with adjacent peripheral nerve technology expertise. Useful analog for nerve-interface device development and FDA pathways.

Others

• Collagen Solutions: Supplier of medical-grade collagen and tissue-based biomaterials used in nerve and wound repair applications — adjacent ecosystem participant and potential supplier to Renerva's pipeline.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/renerva

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds6 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Renerva